» Articles » PMID: 28784700

Serum Iron Protects from Renal Postischemic Injury

Abstract

Renal transplants remain a medical challenge, because the parameters governing allograft outcome are incompletely identified. Here, we investigated the role of serum iron in the sterile inflammation that follows kidney ischemia-reperfusion injury. In a retrospective cohort study of renal allograft recipients (=169), increased baseline levels of serum ferritin reliably predicted a positive outcome for allografts, particularly in elderly patients. In mice, systemic iron overload protected against renal ischemia-reperfusion injury-associated sterile inflammation. Furthermore, chronic iron injection in mice prevented macrophage recruitment after inflammatory stimuli. Macrophages cultured in high-iron conditions had reduced responses to Toll-like receptor-2, -3, and -4 agonists, which associated with decreased reactive oxygen species production, increased nuclear localization of the NRF2 transcription factor, increased expression of the NRF2-related antioxidant response genes, and limited NF-B and proinflammatory signaling. In macrophage-depleted animals, the infusion of macrophages cultured in high-iron conditions did not reconstitute AKI after ischemia-reperfusion, whereas macrophages cultured in physiologic iron conditions did. These findings identify serum iron as a critical protective factor in renal allograft outcome. Increasing serum iron levels in patients may thus improve prognosis of renal transplants.

Citing Articles

Correlation between serum iron levels and pulmonary function: A cross-sectional analysis based on NHANES database 5319 cases.

Su L, Hu S, Wang S, Guo Q, Wei Y Medicine (Baltimore). 2023; 102(50):e36449.

PMID: 38115354 PMC: 10727669. DOI: 10.1097/MD.0000000000036449.


Treatment Options for Anemia in Kidney Transplant Patients: A Review.

Bonomini M, Di Liberato L, Sirolli V Kidney Med. 2023; 5(8):100681.

PMID: 37415623 PMC: 10320602. DOI: 10.1016/j.xkme.2023.100681.


Effect of Intravenous Ferric Carboxymaltose on Exercise Capacity After Kidney Transplantation (EFFECT-KTx): rationale and study protocol for a double-blind, randomised, placebo-controlled trial.

Vinke J, Eisenga M, Sanders J, Berger S, Spikman J, Abdulahad W BMJ Open. 2023; 13(3):e065423.

PMID: 36948568 PMC: 10040026. DOI: 10.1136/bmjopen-2022-065423.


Iron deficiency and cognitive functioning in kidney transplant recipients: findings of the TransplantLines biobank and cohort study.

Vinke J, Ziengs A, Buunk A, van Sonderen L, Gomes-Neto A, Berger S Nephrol Dial Transplant. 2023; 38(7):1719-1728.

PMID: 36662046 PMC: 10310504. DOI: 10.1093/ndt/gfad013.


Iron therapy mitigates chronic kidney disease progression by regulating intracellular iron status of kidney macrophages.

Patino E, Bhatia D, Vance S, Antypiuk A, Uni R, Campbell C JCI Insight. 2022; 8(1).

PMID: 36394951 PMC: 9870080. DOI: 10.1172/jci.insight.159235.


References
1.
Weiss G . Iron and immunity: a double-edged sword. Eur J Clin Invest. 2002; 32 Suppl 1:70-8. DOI: 10.1046/j.1365-2362.2002.0320s1070.x. View

2.
Alejandro V, Scandling Jr J, Sibley R, Dafoe D, Alfrey E, Deen W . Mechanisms of filtration failure during postischemic injury of the human kidney. A study of the reperfused renal allograft. J Clin Invest. 1995; 95(2):820-31. PMC: 295562. DOI: 10.1172/JCI117732. View

3.
Itoh K, Chiba T, Takahashi S, Ishii T, Igarashi K, Katoh Y . An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun. 1997; 236(2):313-22. DOI: 10.1006/bbrc.1997.6943. View

4.
Henique C, Bollee G, Lenoir O, Dhaun N, Camus M, Chipont A . Nuclear Factor Erythroid 2-Related Factor 2 Drives Podocyte-Specific Expression of Peroxisome Proliferator-Activated Receptor γ Essential for Resistance to Crescentic GN. J Am Soc Nephrol. 2015; 27(1):172-88. PMC: 4696572. DOI: 10.1681/ASN.2014111080. View

5.
Herrero-Fresneda I, Torras J, Cruzado J, Condom E, Vidal A, Riera M . Do alloreactivity and prolonged cold ischemia cause different elementary lesions in chronic allograft nephropathy?. Am J Pathol. 2003; 162(1):127-37. PMC: 1851124. DOI: 10.1016/S0002-9440(10)63804-7. View